The DOI matches its Crossref record; 202 of the 202 references it cites were found in a registry or an index.
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Open accessAbstract
T Regulatory cells (Tregs) can have both protective and pathological roles. They maintain immune homeostasis and inhibit immune responses in various diseases, including cancer. Proportions of Tregs in the peripheral blood of some cancer patients increase by approximately two-fold, compared to those in healthy individuals. Tregs contribute to cancer development and progression by suppressing T effector cell functions, thereby compromising tumor killing and promoting tumor growth. Highly immunosuppressive Tregs express upregulated levels of the transcription factor, Forkhead box protein P3 (FoxP3). Elevated levels of FoxP3+ Tregs within the tumor microenvironment (TME) showed a positive correlation with poor prognosis in various cancer patients. Despite the success of immunotherapy, including the use of immune checkpoint inhibitors, a significant proportion of patients show low response rates as a result of primary or acquired resistance against therapy. Some of the mechanisms which underlie the development of therapy resistance are associated with Treg suppressive function. In this review, we describe Treg contribution to cancer development/progression, and the mechanisms of Treg-mediated immunosuppression. We discuss the prognostic significance of FoxP3+ Tregs in different cancers and their potential use as prognostic biomarkers. We also describe potential therapeutic strategies to target Tregs in combination with other types of immunotherapies aiming to overcome tumor resistance and improve clinical outcomes in cancer patients. Overall, understanding the prognostic significance of FoxP3+ Tregs in various cancers and their contribution to therapy resistance could help in the development of more effective targeted therapeutic strategies to enhance the clinical outcomes in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
TIGIT predominantly regulates the immune response via regulatory T cells
Kurtulus, S., Sakuishi, K., Ngiow, S.-F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 551
RetractedControl of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R. S., & Vignali, D. A. A. (2007) · Nature · doi:10.1038/nature06306 · Cited by 2,066
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
A function for interleukin 2 in Foxp3-expressing regulatory T cells
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A., & Rudensky, A. Y. (2005) · Nature Immunology · doi:10.1038/ni1263 · Cited by 1,819
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Yu, X., Harden, K., C Gonzalez, L., Francesco, M., Chiang, E., Irving, B., Tom, I., Ivelja, S., Refino, C. J., Clark, H., et al. (2009) · Nature Immunology · doi:10.1038/ni.1674 · Cited by 1,491
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT
Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., Bates, D. L., Guo, L., Han, A., Ziegler, S. F., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.042 · Cited by 1,189
Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate
Zheng, Y., Josefowicz, S., Chaudhry, A., Peng, X. P., Forbush, K., & Rudensky, A. Y. (2010) · Nature · doi:10.1038/nature08750 · Cited by 1,169
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,161
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
Malek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance
Cao, X., Cai, S. F., Fehniger, T. A., Song, J., Collins, L. I., Piwnica-Worms, D. R., & Ley, T. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.08.014 · Cited by 1,035
Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7229 · Cited by 991
Shang, B., Liu, Y., Jiang, S.-J., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep15179 · Cited by 985
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
TGF-β: A Master of All T Cell Trades
Li, M. O., & Flavell, R. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.025 · Cited by 893
An essential role for the IL-2 receptor in Treg cell function
Chinen, T., Kannan, A. K., Levine, A. G., Fan, X., Klein, U., Zheng, Y., Gasteiger, G., Feng, Y., Fontenot, J. D., & Rudensky, A. Y. (2016) · Nature Immunology · doi:10.1038/ni.3540 · Cited by 888
IL-35-mediated induction of a potent regulatory T cell population
Collison, L. W., Chaturvedi, V., Henderson, A. L., Giacomin, P. R., Guy, C., Bankoti, J., Finkelstein, D., Forbes, K., Workman, C. J., Brown, S. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1952 · Cited by 869
Murai, M., Turovskaya, O., Kim, G., Madan, R., Karp, C. L., Cheroutre, H., & Kronenberg, M. (2009) · Nature Immunology · doi:10.1038/ni.1791 · Cited by 850
Hiraoka, N., Onozato, K., Kosuge, T., & Hirohashi, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0369 · Cited by 831
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
DNA methylation controls Foxp3 gene expression
Polansky, J. K., Kretschmer, K., Freyer, J., Floess, S., Garbe, A., Baron, U., Olek, S., Hamann, A., von Boehmer, H., & Huehn, J. (2008) · European Journal of Immunology · doi:10.1002/eji.200838105 · Cited by 785
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Taylor, A., Verhagen, J., Blaser, K., Akdis, M., & Akdis, C. A. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02321.x · Cited by 720
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1
Ono, M., Yaguchi, H., Ohkura, N., Kitabayashi, I., Nagamura, Y., Nomura, T., Miyachi, Y., Tsukada, T., & Sakaguchi, S. (2007) · Nature · doi:10.1038/nature05673 · Cited by 690
Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316796110 · Cited by 627
Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1886 · Cited by 598
Thymus and Reproduction: Sex-Linked Dysgenesia of the Gonad after Neonatal Thymectomy in Mice
Nishizuka, Y., & Sakakura, T. (1969) · Science · doi:10.1126/science.166.3906.753 · Cited by 591
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 543
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Sawant, D. V., Yano, H., Chikina, M., Zhang, Q., Liao, M., Liu, C., Callahan, D. J., Sun, Z., Sun, T., Tabib, T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0346-9 · Cited by 543
Kouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Roles of regulatory T cells in cancer immunity
Takeuchi, Y., & Nishikawa, H. (2016) · International Immunology · doi:10.1093/intimm/dxw025 · Cited by 523
Wolf, D., Wolf, A. M., Rumpold, H., Fiegl, H., Zeimet, A. G., Muller-Holzner, E., Deibl, M., Gastl, G., Gunsilius, E., & Marth, C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1244 · Cited by 511
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Self-citationTGF-β Family Signaling in Tumor Suppression and Cancer Progression
Seoane, J., & Gomis, R. R. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022277 · Cited by 510
VISTA Regulates the Development of Protective Antitumor Immunity
Le Mercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J., & Wang, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 486
Kobie, J. J., Shah, P. R., Yang, L., Rebhahn, J. A., Fowell, D. J., & Mosmann, T. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6780 · Cited by 466
Generation Ex Vivo of TGF-β-Producing Regulatory T Cells from CD4+CD25− Precursors
Zheng, S. G., Gray, J. D., Ohtsuka, K., Yamagiwa, S., & Horwitz, D. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4183 · Cited by 465
Munn, D. H., Sharma, M. D., & Mellor, A. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4100 · Cited by 457
Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0472 · Cited by 453
Milne, K., Köbel, M., Kalloger, S. E., Barnes, R. O., Gao, D., Gilks, C. B., Watson, P. H., & Nelson, B. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006412 · Cited by 446
Schlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., & Cerwenka, A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201018 · Cited by 438
deLeeuw, R. J., Kost, S. E., Kakal, J. A., & Nelson, B. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3216 · Cited by 437
Petersen, R. P., Campa, M. J., Sperlazza, J., Conlon, D., Joshi, M., Harpole, D. H., & Patz, E. F. (2006) · Cancer · doi:10.1002/cncr.22282 · Cited by 433
Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., & Fu, Y.-X. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041684 · Cited by 432
CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients
Miller, A. M., Lundberg, K., Özenci, V., Banham, A. H., Hellström, M., Egevad, L., & Pisa, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7398 · Cited by 421
Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Wang, F., Sun, J., Yang, Q., Zhang, X., & Lu, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030676 · Cited by 407
Leffers, N., Gooden, M. J. M., de Jong, R. A., Hoogeboom, B.-N., ten Hoor, K. A., Hollema, H., Boezen, H. M., van der Zee, A. G. J., Daemen, T., & Nijman, H. W. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0583-5 · Cited by 402
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401
Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391
Mandapathil, M., Hilldorfer, B., Szczepanski, M. J., Czystowska, M., Szajnik, M., Ren, J., Lang, S., Jackson, E. K., Gorelik, E., & Whiteside, T. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047423 · Cited by 390
Kawai, O., Ishii, G., Kubota, K., Murata, Y., Naito, Y., Mizuno, T., Aokage, K., Saijo, N., Nishiwaki, Y., Gemma, A., et al. (2008) · Cancer · doi:10.1002/cncr.23712 · Cited by 384
Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903879 · Cited by 350
Ladoire, S., Martin, F., & Ghiringhelli, F. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1046-y · Cited by 331
TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Sakuishi, K., Ngiow, S. F., Sullivan, J. M., Teng, M. W. L., Kuchroo, V. K., Smyth, M. J., & Anderson, A. C. (2013) · OncoImmunology · doi:10.4161/onci.23849 · Cited by 328
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89455 · Cited by 325
Extracellular Adenosine-Mediated Modulation of Regulatory T Cells
Ohta, A., & Sitkovsky, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00304 · Cited by 320
The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
Workman, C. J., & Vignali, D. A. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323382 · Cited by 319
Wieczorek, G., Asemissen, A., Model, F., Turbachova, I., Floess, S., Liebenberg, V., Baron, U., Stauch, D., Kotsch, K., Pratschke, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2361 · Cited by 317
Emerging targets in cancer immunotherapy
Burugu, S., Dancsok, A. R., & Nielsen, T. O. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.001 · Cited by 314
Interleukin-35 Limits Anti-Tumor Immunity
Turnis, M. E., Sawant, D. V., Szymczak-Workman, A. L., Andrews, L. P., Delgoffe, G. M., Yano, H., Beres, A. J., Vogel, P., Workman, C. J., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.013 · Cited by 311
Shayan, G., Srivastava, R., Li, J., Schmitt, N., Kane, L. P., & Ferris, R. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1261779 · Cited by 306
Targeting IL-10 Family Cytokines for the Treatment of Human Diseases
Wang, X., Wong, K., Ouyang, W., & Rutz, S. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028548 · Cited by 302
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
Self-citationAcquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Self-citationCurrent status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
Targeting CD73 in the tumor microenvironment with MEDI9447
Hay, C. M., Sult, E., Huang, Q., Mulgrew, K., Fuhrmann, S. R., McGlinchey, K. A., Hammond, S. A., Rothstein, R., Rios-Doria, J., Poon, E., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1208875 · Cited by 287
Tahara-Hanaoka, S. (2004) · International Immunology · doi:10.1093/intimm/dxh059 · Cited by 286
Oweida, A., Hararah, M. K., Phan, A., Binder, D., Bhatia, S., Lennon, S., Bukkapatnam, S., Van Court, B., Uyanga, N., Darragh, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1038 · Cited by 274
Busse, D., de la Rosa, M., Hobiger, K., Thurley, K., Flossdorf, M., Scheffold, A., & Höfer, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812851107 · Cited by 273
Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., & Wang, Y. (2011) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.56 · Cited by 267
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Li, X.-Y., Moesta, A. K., Xiao, C., Nakamura, K., Casey, M., Zhang, H., Madore, J., Lepletier, A., Aguilera, A. R., Sundarrajan, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0541 · Cited by 264
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
Wang, J., Wu, G., Manick, B., Hernandez, V., Renelt, M., Erickson, C., Guan, J., Singh, R., Rollins, S., Solorz, A., et al. (2019) · Immunology · doi:10.1111/imm.13001 · Cited by 263
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2009) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 259
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Tao, H., Mimura, Y., Aoe, K., Kobayashi, S., Yamamoto, H., Matsuda, E., Okabe, K., Matsumoto, T., Sugi, K., & Ueoka, H. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.002 · Cited by 253
T Regulatory Cells and Priming the Suppressive Tumor Microenvironment
Paluskievicz, C. M., Cao, X., Abdi, R., Zheng, P., Liu, Y., & Bromberg, J. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02453 · Cited by 251
Ralph, C., Elkord, E., Burt, D. J., O'Dwyer, J. F., Austin, E. B., Stern, P. L., Hawkins, R. E., & Thistlethwaite, F. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2870 · Cited by 250
Self-citationKurose, K., Ohue, Y., Wada, H., Iida, S., Ishida, T., Kojima, T., Doi, T., Suzuki, S., Isobe, M., Funakoshi, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0357 · Cited by 241
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 236
Self-citationNaing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Patel, M. R., Wong, D. J., Falchook, G. S., Pant, S., Whiteside, M., Rasco, D. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1106 · Cited by 222
T‐cell tolerance and the multi‐functional role of IL‐2R signaling in T‐regulatory cells
Cheng, G., Yu, A., & Malek, T. R. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01004.x · Cited by 220
Regulatory T cells: a potential target in cancer immunotherapy
Shitara, K., & Nishikawa, H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13625 · Cited by 214
Correale, P., Rotundo, M. S., Del Vecchio, M. T., Remondo, C., Migali, C., Ginanneschi, C., Tsang, K. Y., Licchetta, A., Mannucci, S., Loiacono, L., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32f01 · Cited by 210
Perrone, G., Ruffini, P. A., Catalano, V., Spino, C., Santini, D., Muretto, P., Spoto, C., Zingaretti, C., Sisti, V., Alessandroni, P., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.017 · Cited by 210
Seo, N., Hayakawa, S., Takigawa, M., & Tokura, Y. (2001) · Immunology · doi:10.1046/j.1365-2567.2001.01279.x · Cited by 206
Thornton, A. M., Lu, J., Korty, P. E., Kim, Y. C., Martens, C., Sun, P. D., & Shevach, E. M. (2019) · European Journal of Immunology · doi:10.1002/eji.201847935 · Cited by 203
Chiba, T., Ohtani, H., Mizoi, T., Naito, Y., Sato, E., Nagura, H., Ohuchi, A., Ohuchi, K., Shiiba, K., Kurokawa, Y., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602201 · Cited by 201
Griffiths, R. W., Elkord, E., Gilham, D. E., Ramani, V., Clarke, N., Stern, P. L., & Hawkins, R. E. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0318-z · Cited by 200
Self-citationSayour, E. J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J. H., & Mitchell, D. A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1651-7 · Cited by 196
FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity
Whiteside, T. L. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1451514 · Cited by 196
Shen, Z., Zhou, S., Wang, Y., Li, R.-L., Zhong, C., Liang, C., & Sun, Y. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0816-9 · Cited by 195
Lech-Maranda, E. (2004) · Blood · doi:10.1182/blood-2003-06-1850 · Cited by 187
Suzuki, H., Chikazawa, N., Tasaka, T., Wada, J., Yamasaki, A., Kitaura, Y., Sozaki, M., Tanaka, M., Onishi, H., Morisaki, T., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0781-9 · Cited by 180
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
Stewart, C. A., Metheny, H., Iida, N., Smith, L., Hanson, M., Steinhagen, F., Leighty, R. M., Roers, A., Karp, C. L., Müller, W., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65180 · Cited by 173
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
Eid, R. A., Samara, R. N., Ozbun, L. L., Abdalla, M. Y., Berzofsky, J. A., Friedman, K. M., Mkrtichyan, M., & Khleif, S. N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0095 · Cited by 167
Yang, A. S., & Lattime, E. C. (2003) · PubMed · Cited by 165
Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis
Zhao, S., Wu, D., Wu, P., Wang, Z., & Huang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139598 · Cited by 164
Halak, B. K., Maguire, H., & Lattime, E. C. (1999) · PubMed · Cited by 158
Toor, S. M., Murshed, K., Al-Dhaheri, M., Khawar, M., Abu Nada, M., & Elkord, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02936 · Cited by 158
Self-citationHaas, M., Dimmler, A., Hohenberger, W., Grabenbauer, G. G., Niedobitek, G., & Distel, L. V. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-65 · Cited by 154
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153
Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell, D. J., Wunderlich, J. R., Merino, M. J., & Rosenberg, S. A. (2008) · Blood · doi:10.1182/blood-2008-06-163048 · Cited by 152
Autocrine Adenosine Signaling Promotes Regulatory T Cell–Mediated Renal Protection
Kinsey, G. R., Huang, L., Jaworska, K., Khutsishvili, K., Becker, D. A., Ye, H., Lobo, P. I., & Okusa, M. D. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010070 · Cited by 150
Chau, G., Wu, C.-W., Lui, W., Chang, T.-J., Kao, H.-L., Wu, L., King, K., Loong, C., Hsia, C.-Y., & Chi, C. (2000) · Annals of Surgery · doi:10.1097/00000658-200004000-00015 · Cited by 149
Li, F., Sun, Y., Huang, J., Xu, W., Liu, J., & Yuan, Z. (2019) · Cancer Medicine · doi:10.1002/cam4.2596 · Cited by 149
d'Hennezel, E. B., Dhuban, K. B., Torgerson, T. R., & Piccirillo, C. A. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-100759 · Cited by 148
Kim, S. T., Jeong, H., Woo, O. H., Seo, J. H., Kim, A., Lee, E. S., Shin, S. W., Kim, Y. H., Kim, J. S., & Park, K. H. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182467d90 · Cited by 146
Takenaka, M., Seki, N., Toh, U., Hattori, S., Kawahara, A., Yamaguchi, T., Koura, K., Takahashi, R., Otsuka, H., Takahashi, H., et al. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.107 · Cited by 146
Functional reprogramming of regulatory T cells in the absence of Foxp3
Charbonnier, L.-M., Cui, Y., Stephen-Victor, E., Harb, H., Lopez, D., Bleesing, J. J., Garcia-Lloret, M. I., Chen, K., Ozen, A., Carmeliet, P., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0442-x · Cited by 145
On the mechanism of anti-CD39 immune checkpoint therapy
Allard, D., Allard, B., & Stagg, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000186 · Cited by 141
Liotta, F., Gacci, M., Frosali, F., Querci, V., Vittori, G., Lapini, A., Santarlasci, V., Serni, S., Cosmi, L., Maggi, L., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09555.x · Cited by 137
Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis
Pereira, L. M. S., Gomes, S. T. M., Ishak, R., & Vallinoto, A. C. R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00605 · Cited by 137
Khaja, A. S. S., Toor, S. M., Salhat, H. E., Faour, I., Haq, N. U., Ali, B. R., & Elkord, E. (2017) · Oncotarget · doi:10.18632/oncotarget.16565 · Cited by 132
Self-citationNemunaitis, J. J., Fong, T. C., Shabe, P., Martineau, D., & Ando, D. G. (2001) · Cancer Investigation · doi:10.1081/cnv-100102550 · Cited by 131
Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells
Sitkovsky, M. V., Lukashev, D. E., Deaglio, S., Dwyer, K. M., Robson, S. C., & Ohta, A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.23 · Cited by 129
Lee, J., Won, H. S., Sun, D. S., Hong, J. H., & Ko, Y. H. (2018) · Medicine · doi:10.1097/md.0000000000011769 · Cited by 129
Intraepithelial T cells and tumor proliferation
Adams, S. F., Levine, D. A., Cadungog, M. G., Hammond, R., Facciabene, A., Olvera, N., Rubin, S. C., Boyd, J. A., Gimotty, P. A., & Coukos, G. (2009) · Cancer · doi:10.1002/cncr.24317 · Cited by 121
Saleh, R., Toor, S. M., Khalaf, S., & Elkord, E. (2019) · Vaccines · doi:10.3390/vaccines7040149 · Cited by 117
Self-citationInoue, N., Watanabe, M., Morita, M., Tomizawa, R., Akamizu, T., Tatsumi, K., Hidaka, Y., & Iwatani, Y. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04229.x · Cited by 113
Mbd2 Promotes Foxp3 Demethylation and T-Regulatory-Cell Function
Wang, L., Liu, Y., Han, R., Beier, U. H., Thomas, R. M., Wells, A. D., & Hancock, W. W. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00144-13 · Cited by 112
Qin, A., Wen, Z., Zhou, Y., Li, Y., Li, Y., Luo, J., Ren, T., & Xu, L. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12003 · Cited by 110
Ehrentraut, H., Westrich, J. A., Eltzschig, H. K., & Clambey, E. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032416 · Cited by 110
TGFβ1 and Treg cells: alliance for tolerance
Bommireddy, R., & Doetschman, T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.005 · Cited by 108
TGF‐β–responsive CAR‐T cells promote anti‐tumor immune function
Hou, A. J., Chang, Z. L., Lorenzini, M. H., Zah, E., & Chen, Y. Y. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10097 · Cited by 106
Functional Plasticity of Dendritic Cell Subsets as Mediated by CD40 Versus B7 Activation
Grohmann, U., Bianchi, R., Orabona, C., Fallarino, F., Vacca, C., Micheletti, A., Fioretti, M. C., & Puccetti, P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.5.2581 · Cited by 106
Poor clinical outcome of patients with Hodgkin's Disease and elevated interleukin-10 serum levels
Bohlen, H., Kessler, M. M., Sextro, M., Diehl, V., & Tesch, H. (2000) · Annals of Hematology · doi:10.1007/s002770050564 · Cited by 104
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Young, A., Ngiow, S. F., Madore, J., Reinhardt, J., Landsberg, J., Chitsazan, A., Rautela, J., Bald, T., Barkauskas, D. S., Ahern, E. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0393 · Cited by 103
Seminerio, I., Descamps, G., Dupont, S., Marrez, L. G. D., Laigle, J.-A., Lechien, J. R., Kindt, N., Journé, F., & Saussez, S. (2019) · Cancers · doi:10.3390/cancers11020227 · Cited by 103
Yoon, H. H., Orrock, J. M., Foster, N. R., Sargent, D. J., Smyrk, T. C., & Sinicrope, F. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042274 · Cited by 101
Regulatory T cells induced by B cells: a novel subpopulation of regulatory T cells
Chien, C., & Chiang, B. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0391-3 · Cited by 100
Kotsakis, A. P., Koinis, F., Katsarou, A., Gioulbasani, M., Aggouraki, D., Kentepozidis, N. K., Georgoulias, V., & Vetsika, E. (2016) · Scientific Reports · doi:10.1038/srep39247 · Cited by 99
Flynn, M. J., & Hartley, J. A. (2017) · British Journal of Haematology · doi:10.1111/bjh.14770 · Cited by 99
Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells
Ondondo, B., Jones, E., Godkin, A. J., & Gallimore, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00197 · Cited by 98
Wang, S., Gao, X., Shen, G., Wang, W., Li, J., Zhao, J., Wei, Y.-Q., & Edwards, C. K. (2016) · Scientific Reports · doi:10.1038/srep24249 · Cited by 96
Masoumi, E., Jafarzadeh, L., Mirzaei, H. R., Alishah, K., Fallah-Mehrjardi, K., Rostamian, H., Khakpoor-Koosheh, M., Meshkani, R., Noorbakhsh, F., & Hadjati, J. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01546-6 · Cited by 95
Khaja, A. S. S., Toor, S. M., Salhat, H. E., Ali, B. R., & Elkord, E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00619 · Cited by 93
Self-citationCutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells
Wang, C. J., Kenefeck, R., Wardzinski, L., Attridge, K., Manzotti, C. N., Schmidt, E. M., Qureshi, O., Sansom, D. M., & Walker, L. S. K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200972 · Cited by 92
García-Hernández, M. D. L. L., Hernández‐Pando, R., Gariglio, P., & Berumen-Campos, J. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01363.x · Cited by 91
Tumour islet Foxp3+T-cell infiltration predicts poor outcome in nonsmall cell lung cancer
O’Callaghan, D. S., Rexhepaj, E., Gately, K. A., Coate, L. E., Delaney, D., O’Donnell, D. M., Kay, E. W., O’Connell, F., Gallagher, W. M., & O'Byrne, K. J. (2015) · European Respiratory Journal · doi:10.1183/13993003.00176-2014 · Cited by 87
Echarti, A., Hecht, M., Büttner-Herold, M., Haderlein, M., Hartmann, A., Fietkau, R., & Distel, L. (2019) · Cancers · doi:10.3390/cancers11091398 · Cited by 87
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy
Munn, D. H., Sharma, M. D., & Johnson, T. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1351 · Cited by 84
Yang, Z., Grote, D. M., Ziesmer, S. C., Xiu, B., Yates, N. R., Secreto, F. J., Hodge, L. S., Witzig, T. E., Novak, A. J., & Ansell, S. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059456 · Cited by 78
Tumor-infiltrating regulatory T cells: origins and features.
Deng, G. (2018) · Europe PMC (PubMed Central) · Cited by 76
Khan, S. S., Burt, D. J., Ralph, C., Thistlethwaite, F. C., Hawkins, R. E., & Elkord, E. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.09.011 · Cited by 73
Self-citationComparison of stable human Treg and Th clones by transcriptional profiling
Stockis, J., Fink, W., François, V., Connerotte, T., Smet, C. D., Knoops, L., van der Bruggen, P., Boon, T., Coulie, P. G., & Lucas, S. (2009) · European Journal of Immunology · doi:10.1002/eji.200838807 · Cited by 72
Extracellular adenosine metabolism in immune cells in melanoma
Umansky, V., Shevchenko, I., Bazhin, A. V., & Utikal, J. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1553-8 · Cited by 69
Lee, D. J., & Taylor, A. W. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300182 · Cited by 69
Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity
Azambuja, J. H., Ludwig, N., Braganhol, E., & Whiteside, T. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225698 · Cited by 65
Dedobbeleer, O., Stockis, J., van der Woning, B., Coulie, P. G., & Lucas, S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601882 · Cited by 64
Zhou, Y., Shao, N., AiErken, N., Xie, C., Ye, R., Qian, X., Hu, Z., Zhang, J., & Lin, Y. (2017) · Journal of Cancer · doi:10.7150/jca.21030 · Cited by 64
Peng, L., Zhuang, Y., Shi, Y., Zhao, Y., Wang, T., Chen, N., Cheng, P., Liu, T., Liu, X.-F., Zhang, J., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1277-6 · Cited by 62
Circulating IL-35 in pancreatic ductal adenocarcinoma patients
Jin, P., Ren, H., Sun, W., Xin, W., Zhang, H., & Hao, J. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.09.018 · Cited by 58
Zhao, S., Jiang, T., Zhang, L., Yang, H. J., Liu, X., Jia, Y., & Zhou, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9130 · Cited by 52
Polanczyk, M. J., Walker, E., Haley, D. P., Guerrouahen, B. S., & Akporiaye, E. T. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1967-3 · Cited by 51
Han, K. L., Thomas, S. V. M., Koontz, S. M., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201325 · Cited by 50
Liu, C., Cheng, H., Luo, G., Lu, Y., Jin, K., Guo, M., Ni, Q., & Yu, X. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4032 · Cited by 50
Helios—controller of Treg stability and function
Chougnet, C. A., & Hildeman, D. A. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.07.37 · Cited by 49
Hwang, H. K., Kim, H., Kim, S. H., Choi, J., Kang, C. M., Kim, K. S., & Lee, W. J. (2016) · Oncology Letters · doi:10.3892/ol.2016.5252 · Cited by 49
Interleukin-35 as an Emerging Player in Tumor Microenvironment
Xue, W., Yan, D., & Kan, Q. (2019) · Journal of Cancer · doi:10.7150/jca.29170 · Cited by 46
Molecular Pathways: Interleukin-35 in Autoimmunity and Cancer
Pylayeva‐Gupta, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0743 · Cited by 44
Sun, D., Zhao, M., Xia, M. X., Li, L., & Jiang, Y. (2011) · Medical Oncology · doi:10.1007/s12032-011-9903-2 · Cited by 43
The prognostic value of FOXP3+ T regulatory cells in colorectal cancer.
Vlad, C. I., Kubelac, P. M., Fetică, B., Vlad, D., Irimie, A., & Achimaș-Cădariu, P. (2015) · PubMed · Cited by 38
Ma, H., Gao, W., Sun, X., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/6985031 · Cited by 35
Profiles of tumor‑infiltrating immune cells in renal cell carcinoma and their clinical implications
Zhu, G., Pei, L., Yin, H., Fan, L., Li, X., Zhu, X., He, W., & Gou, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.10896 · Cited by 33
Cao, X., Kang, Y., Tai, P., Zhang, P., Lin, X. H., Xu, F., Nie, Z., & He, B. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102510 · Cited by 33
The appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer
Xu, W., Liu, H., Song, J., Fu, H.-X., Qiu, L., Zhang, B.-F., Li, H.-Z., Bai, J., & Zheng, J.-N. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1500-7 · Cited by 31
Helios expression in FoxP3+T regulatory cells
Elkord, E., & al-Ramadi, B. K. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.711310 · Cited by 30
Self-citationBecker, W., Nagarkatti, M., & Nagarkatti, P. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00688 · Cited by 26
Nair, V. S., Toor, S. M., Taouk, G. M., Pfister, G., Ouararhni, K., Alajez, N. M., & Elkord, E. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900575 · Cited by 23
Self-citationFOXP3 and Its Cofactors as Targets of Immunotherapies
Nagai, Y., Lam, L., Greene, M. I., & Zhang, H. (2019) · Engineering · doi:10.1016/j.eng.2019.01.001 · Cited by 20
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Koyama, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002591 · Cited by 305
Dang, K., Castello, G., Clarke, S. C., Li, Y., Balasubramani, A., Boudreau, A., Davison, L., Harris, K. E., Pham, D., Sankaran, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002488 · Cited by 76
Metadata
- Authors
- Saleh, R., & Elkord, E.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 490
- Pages
- 174-185
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W3044473529
- Cited by
- 352
- References
- 202
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.